

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number  
**WO 03/057843 A2**

- (51) International Patent Classification<sup>7</sup>: **C12N** Sundbyberg (SE). **HART, Lucy, Vulchanova** [BG/US]; 2117 Niles Avenue, St. Paul, MN 55116 (US).
- (21) International Application Number: PCT/US02/41751
- (22) International Filing Date:  
31 December 2002 (31.12.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/346,171 31 December 2001 (31.12.2001) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 60/346,171 (CON)  
Filed on 31 December 2001 (31.12.2001)
- (71) Applicant (for all designated States except US): **ALGOS THERAPEUTICS, INC.** [US/US]; 4335 Rosewood Lane North, Plymouth, MN 55442 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **SHUSTER, Samuel, J.** [US/US]; 6712 Apache Road, Edina, MN 55439 (US). **ARVIDSSON, Ulf, N., G.** [SE/SE]; Gardstigen 4, S-Lidingo (SE). **STONE, Laura, S.** [CA/US]; 2242 Nevada Avenue South, Apt. 19, St. Louis Park, MN 55426 (US). **ZHANG, Hong-Yan** [CN/SE]; Sevensvagen 4, S-
- (74) Agent: **ELLINGER, Mark, S.**; Fish & Richardson P.C., P.A., Suite 3300, 60 South Sixth Street, Minneapolis, MN 55402 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 03/057843 A2**

(54) Title: METHODS AND MATERIALS FOR MODULATING TRPC4

(57) Abstract: The invention relates to antisense oligonucleotides, compositions and method useful for modulating the expression of TRPC4. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TRPC4.

## METHODS AND MATERIALS FOR MODULATING TRPC4

### TECHNICAL FIELD

This invention relates to antisense oligonucleotides targeted to specific nucleotide sequences. In particular, the invention pertains to antisense oligonucleotides targeted to the nucleic acid encoding the TRPC4, and to their use for reducing cellular levels of TRPC4.

### BACKGROUND

TRPC4 belongs to the family of transient receptor potential channels (TRPC). See, for example, McKay et al., 2000, *Biochem. J.*, 351:735-746; Mizuno et al., 1999, *Brain Res. Mol. Brain Res.*, 64:41-51; and Warnat et al., 1999, *J. Physiol.*, 518:631-638. Each subunit of these channels appears to have six transmembrane regions and intracellular amino- and carboxy-termini. The TRPC family has been divided into three subfamilies based on sequence homology and functional properties. See, Harteneck et al., 2000, *Trends Neurosci.*, 23:159-166.

TRPC4 is a member of a subfamily of short TRPCs, which have a short N-terminus containing several ankyrin domains. TRPC4 reportedly is linked to the calcium release-activated current, originally described in mast cells and T-lymphocytes. See, Phillip et al., 2000, *J. Biol. Chem.*, 275:23965-23972. Regulation of TRPC4 by calcium store depletion is also suggested by the direct interaction of TRPC4 with inositol triphosphate receptors, which mediate the release of calcium from intracellular stores. See, for example, Tang et al., 2001, *J. Biol. Chem.*, 276:21303-21310; and Mery et al., 2001, *FEBS Lett.*, 487:377-383.

### SUMMARY

TRPC4 immunoreactivity is apparent in rat and human sensory neurons and superficial dorsal horn of spinal cord – an area implicated in nociception and chronic pain. This localization is consistent with functional evidence for a calcium store operated

channel in sensory neurons. See, Usachev & Thayer, 1999, *J. Physiol.*, 519:115-130. The apparent role of TRPC4 in regulating intracellular calcium levels suggests that interfering with the function of this channel could be used to modulate the activity of sensory neurons, and to thereby modulate pain sensation in a subject suffering from chronic pain.

Antisense oligonucleotides can be targeted to specific nucleic acid molecules, to thereby reduce expression of specific nucleic acid molecules. For example, antisense oligonucleotides targeted to TRPC4 mRNA could be used therapeutically to reduce the level of TRPC4 receptors in a patient suffering from chronic pain.

One challenge in generating useful antisense oligonucleotides is identifying nucleic acid segments within a target mRNA that are suitable targets for antisense molecules. Antisense oligonucleotides typically are targeted to segments within a target mRNA based on, for example, the function of those segments (*e.g.*, translation start site, coding sequence, etc.). Such targeting approaches are often unsuccessful because they do not account for the tertiary structure of the specific mRNA target. Native mRNA generally is folded into a complex secondary and tertiary structure, rendering sequences on the interior of such folded molecules inaccessible to antisense oligonucleotides. Only antisense molecules directed to accessible portions of a native mRNA could effectively hybridize to the mRNA and potentially bring about a desired result. Therefore, TRPC4 antisense molecules useful to reduce levels of TRPC4 and alleviate pain should be targeted to accessible mRNA sequences.

The invention provides isolated antisense oligonucleotides that specifically hybridize to accessible regions of native TRPC4 mRNA. Such antisense oligonucleotides can inhibit production of TRPC4 and can be used therapeutically to reduce TRPC4 levels. The invention provides isolated antisense oligonucleotides that specifically hybridize within an accessible region of TRPC4 mRNA in its native form, wherein the antisense oligonucleotides inhibit production of TRPC4. The invention also provides methods for decreasing production of TRPC4 in cells or tissues. The method involves contacting cells or tissues with an antisense oligonucleotide that specifically hybridizes within an accessible region of TRPC4 mRNA.

The invention features isolated antisense oligonucleotides consisting essentially of 10 to 50 nucleotides and compositions containing such antisense oligonucleotides. The oligonucleotide can specifically hybridize within an accessible region of the rat TRPC4 mRNA in its native state, wherein the accessible region is defined by nucleotides 43  
5 through 86, 325 through 342, 438 through 461, 624 through 641, 928 through 949, 1123 through 1132, 1190 through 1209, 1433 through 1450, 1806 through 1824, 2313 through 2331, 2499 through 2512, or 2855 through 2875. The antisense oligonucleotide of the invention also can inhibit the production of TRPC4.

The invention also features compositions comprising such isolated antisense  
10 oligonucleotides. The compositions can include a plurality of isolated antisense oligonucleotides, wherein each antisense oligonucleotide specifically hybridizes within a different accessible region.

The invention also features a nucleic acid construct that includes a regulatory element operably linked to a nucleic acid encoding a transcript that specifically hybridizes  
15 within one or more accessible regions of TRPC4 mRNA in its native form. Host cell that contain such nucleic acids are also provided.

The invention features a method of identifying a compound that modulates pain in a mammal. Such a method can include contacting cells comprising a TRPC4 nucleic acid with a compound; and detecting the amount of TRPC4 RNA or TRPC4 polypeptide in or  
20 secreted from the cell. Generally, a difference in the amount of TRPC4 RNA or TRPC4 polypeptide produced in the presence of the compound compared to the amount of TRPC4 RNA or TRPC4 polypeptide produced in the absence of the compound is an indication that the compound modulates pain in the mammal. The method can further include testing the compound in a mammal.

25 Typically, the amount of TRPC4 RNA is determined by Northern blotting, while the amount of TRPC4 polypeptide is determined by Western blotting. Such a compound can be an antisense oligonucleotide that specifically hybridizes within an accessible region of TRPC4 mRNA in its native form. The antisense oligonucleotide can inhibit production of TRPC4.

30 The invention also provides a method for modulating pain in a mammal. Such a method includes administering a compound that modulates the expression of TRPC4 to

the mammal. Such a compound can be an antisense oligonucleotide that specifically hybridizes within an accessible region of TRPC4 mRNA in its native form. The antisense oligonucleotide can inhibit production of TRPC4. For example, the pain can be from diabetic neuropathy, postherpetic neuralgia, fibromyalgia, surgery, or chronic back pain.

5 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references  
10 mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

## 15 DESCRIPTION OF DRAWINGS

Figure 1 is the nucleotide sequence rat TRPC4 (SEQ ID NO:1). GenBank Accession No. NM053434.

Figure 2 is the nucleotide sequence human TRPC4 (SEQ ID NO:2). GenBank Accession No. NM016179.

20 Figure 3A and Figure 3B are line graphs depicting results of nociceptive testing in rats: 1) after catheterization but before induction of chronic neuropathic pain; 2) after induction of chronic neuropathic pain but before antisense treatment; and 3) after antisense treatment. Figure 3A depicts results in rats subjected to a thermal stimulus, and Figure 3B depicts results in rats subjected to a mechanical stimulus.

25 Figure 4A and Figure 4B are line graphs depicting the results of nociceptive testing in rats: 1) after catheterization but before induction of chronic inflammatory pain; 2) after induction of chronic inflammatory pain but before antisense treatment; and 3) after antisense treatment. Figure 4A depicts results in rats subjected to a thermal stimulus, and Figure 4B depicts results in rats subjected to a mechanical stimulus.

30

## DETAILED DESCRIPTION

The invention provides antisense molecules, particularly oligonucleotides, useful for modulating the function of target nucleic acid molecules. A “target nucleic acid” can be RNA and can be DNA, including cDNA, genomic DNA, and synthetic (*e.g.*,  
5 chemically synthesized) DNA. A target nucleic acid can be double-stranded, and can be single-stranded (*i.e.*, a sense or an antisense single strand). In some embodiments, a target nucleic acid encodes a TRPC4 polypeptide. Thus, “target nucleic acids” include DNA encoding TRPC4, RNA (including pre-mRNA and mRNA) transcribed from such  
10 DNA, and cDNA derived from such RNA. Figures 1 and 2 provide nucleic acid sequences encoding rat and human TRPC4 polypeptides (SEQ ID NO:1 and SEQ ID NO:2, respectively). An “antisense” molecule contains nucleic acids or nucleic acid analogs, and can specifically hybridize to a target nucleic acid. “Antisense technology” refers to the modulation of function of a target nucleic acid by an antisense oligonucleotide.

15 “Hybridization” means hydrogen bonding, which can be Watson-Crick, Hoogsteen, or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. “Complementary” refers to the capacity for precise pairing between two nucleotides. For example, adenine and thymine, and guanine and cytosine, respectively, are complementary nucleotide bases (often referred to as “bases”)  
20 that pair via hydrogen bonds.

If a nucleotide at a particular position of a target nucleic acid is capable of hydrogen bonding with a nucleotide within an oligonucleotide (*e.g.*, a candidate antisense molecule), then the oligonucleotide is considered to be complementary to the target nucleic acid at that position. An oligonucleotide and a target nucleic acid are  
25 complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides that can hydrogen bond with each other. Thus, “specifically hybridizable” refers to such degree of complementarity or precise pairing that stable and specific binding occurs between an oligonucleotide and a target nucleic acid.

30 It is understood in the art that the sequence of an antisense oligonucleotide need not be 100% complementary to that of its target nucleic acid to be specifically

hybridizable. An antisense oligonucleotide is specifically hybridizable when (a) binding of the oligonucleotide to the target nucleic acid interferes with the normal function of the target DNA or RNA, and (b) there is sufficient complementarity to avoid non-specific binding of the antisense oligonucleotide to non-target nucleic acids when specific binding is desired, *i.e.*, under *in vitro* assay conditions or under *in vivo* physiological conditions for assays or therapy.

The stringency of *in vitro* hybridization conditions can be adjusted to affect the degree of complementarity or precise pairing required for specific hybridization of an oligonucleotide to a target nucleic acid. The stringency of *in vitro* hybridization depends on temperature, time, and salt concentration (see, *e.g.*, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, NY, 1989). Typically, conditions of high to moderate stringency are used for specific hybridization *in vitro*, such that hybridization occurs between substantially similar nucleic acids, but not between dissimilar nucleic acids. Specific hybridization conditions are hybridization in 5X SSC (0.75 M sodium chloride/0.075 M sodium citrate) for 1 hour at 40°C with shaking, followed by washing 10 times in 1X SSC at 40°C and 5 times in 1X SSC at room temperature. Oligonucleotides that specifically hybridize to a target nucleic acid can be identified by recovering the oligonucleotides from oligonucleotide/target hybridization duplexes (*e.g.*, by boiling) and sequencing the recovered oligonucleotides.

*In vivo* hybridization conditions are intracellular conditions (*e.g.*, physiological pH and intracellular ionic conditions) that affect the hybridization of antisense oligonucleotides to target sequences. *In vivo* conditions can be mimicked *in vitro* using relatively low stringency conditions, such as those used in the RiboTAG™ technology described below. For example, hybridization can be carried out *in vitro* in 2X SSC (0.3 M sodium chloride/0.03 M sodium citrate), 0.1% SDS at 37°C. Alternatively, a wash solution containing 4X SSC, 0.1% SDS can be used at 37°C, with a final wash in 1X SSC at 45°C.

Specific hybridization of an antisense molecule with a target nucleic acid can interfere with the normal function of the target nucleic acid. For a target DNA, antisense technology can disrupt replication and transcription. For a target RNA, antisense technology can disrupt, for example, translocation of the RNA to the site of protein

translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity of the RNA. Antisense technology can also facilitate nucleolytic degradation of a target RNA. The overall effect of such interference with target nucleic acid function is, in the case of a nucleic acid encoding TRPC4, modulation of the expression of TRPC4. In the context of the present invention, “modulation” means a decrease in the expression of a gene and/or a decrease in cellular levels or activity of the protein encoded by a gene.

#### *Identification of Target Sequences for TRPC4 Antisense Oligonucleotides*

10 Antisense oligonucleotides preferably are directed at specific regions within a target nucleic acid. The process of “targeting” an antisense oligonucleotide typically begins with identifying a candidate target nucleic acid whose function is to be modulated. This nucleic acid can be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state.

15 The targeting process also involves identifying a region or regions within a target nucleic acid where an antisense interaction can occur such that a desired effect is achieved. The desired effect can be, for example, modulation of TRPC4 expression or detection of TRPC4 mRNA (*e.g.*, by using a detectably labeled antisense oligonucleotide). Antisense oligonucleotides have been directed at regions encompassing the translation initiation or termination codon of the open reading frame (ORF) of a gene. Antisense oligonucleotides have also been directed at ORFs, at the 5' and 3' untranslated regions of genes, and at intron regions and intron-exon junction regions.

25 Knowledge of the sequence and domain structure (*e.g.*, the location of translation initiation codons, exons, or introns) of a target nucleic acid, however, is generally not sufficient to ensure that an antisense oligonucleotide directed to a specific region will effectively bind to and modulate the function of the target nucleic acid. In its native state, an mRNA molecule is folded into complex secondary and tertiary structures, and sequences on the interior of such folded structures generally are inaccessible to antisense oligonucleotides. For maximal effectiveness, antisense oligonucleotides can be directed to regions of a target mRNA that are most accessible, *i.e.*, regions at or near the surface of a folded mRNA molecule.

Accessible regions of an mRNA molecule can be identified by, for example, the RiboTAG™ method, or mRNA Accessible Site Tagging (MAST), as described in PCT App. No. SE01/02054.

Using the RiboTAG™ method, oligonucleotides that can interact with a test mRNA in its native state (*i.e.*, under physiological conditions) are selected and sequenced, thus leading to the identification of regions within the test mRNA that are accessible to antisense molecules. In a version of the RiboTAG™ protocol, the test mRNA is produced by *in vitro* transcription and is then immobilized, for example by covalent or non-covalent attachment to a bead or a surface (*e.g.*, a magnetic bead). The immobilized test mRNA is then contacted by a population of oligonucleotides, wherein a portion of each oligonucleotide contains a different, random region. Oligonucleotides that can hybridize to the test mRNA under conditions of low stringency are separated from the remainder of the population (*e.g.*, by precipitation of the magnetic beads). The selected oligonucleotides then can be amplified and sequenced; these steps of the protocol are facilitated if the random regions within each oligonucleotide are flanked on one or both sides by non-random regions that can serve as primer binding sites for PCR amplification.

In general, oligonucleotides useful for RiboTAG™ technology contain between 15 and 18 random bases, flanked on either side by non-random regions. These oligonucleotides are contacted by a test mRNA under conditions that do not disrupt the native structure of the mRNA (*e.g.*, in the presence of medium pH buffering, salts that modulate annealing, and detergents and/or carrier molecules that minimize non-specific interactions). Typically, hybridization is carried out at 37 to 40°C, in a solution containing 1X to 5X SSC and about 0.1% SDS. Non-specific interactions can be further minimized by blocking the non-random sequence(s) in each oligonucleotide with the primers that will be used for PCR amplification of the selected oligonucleotides.

As described herein, accessible regions of nucleic acids encoding rat TRPC4 have been mapped. Thus, antisense oligonucleotides of the invention can specifically hybridize within one or more accessible regions defined by: nucleotides 43 through 86, 325 through 342, 438 through 461, 624 through 641, 928 through 949, 1123 through 1132, 1190 through 1209, 1433 through 1450, 1806 through 1824, 2313 through 2331,

2499 through 2512, or 2855 through 2875. of SEQ ID NO:1. Using the methods disclosed herein, those of skill in the art can, as a matter of routine experimentation, identify accessible regions of nucleic acids encoding human TRPC4 (SEQ ID NO:2).

Once accessible regions of a target nucleic acid have been identified, those of skill  
5 in the art can, as a matter of routine, design antisense oligonucleotides that specifically hybridize to the target nucleic acid. It should be noted that an antisense oligonucleotide may consist essentially of a nucleotide sequence that specifically hybridizes with an accessible region set out above. Such antisense oligonucleotides, however, may contain additional flanking sequences of 5 to 10 nucleotides at either end. Flanking sequences  
10 can include, for example, additional sequence of the target nucleic acid or primer sequence.

For maximal effectiveness, further criteria can be applied to the design of antisense oligonucleotides. Such criteria are known in the art, and are widely used, for example, in the design of oligonucleotide primers. These criteria include the lack of  
15 predicted secondary structure of a potential antisense oligonucleotide, an appropriate GC content (*e.g.*, approximately 50%), and the absence of sequence motifs such as single nucleotide repeats (*e.g.*, GGGG runs).

#### *TRPC4 Antisense Oligonucleotides*

20 Once one or more accessible target regions have been identified, antisense oligonucleotides sufficiently complementary to the target nucleic acid (*i.e.*, that hybridize with sufficient strength and specificity to give the desired effect) can be synthesized. In the context of the present invention, the desired effect is the modulation of TRPC4 expression such that cellular TRPC4 levels are reduced. The effectiveness of an antisense  
25 oligonucleotide to modulate expression of a target nucleic acid can be evaluated by measuring levels of the mRNA or protein products of the target nucleic acid (*e.g.*, by Northern blotting, RT-PCR, Western blotting, ELISA, or immunohistochemical staining).

In some embodiments, it may be useful to target multiple accessible regions of a target nucleic acid. In such embodiments, multiple antisense oligonucleotides can be  
30 used that each specifically hybridize to the same accessible region or to different

accessible regions. Multiple antisense oligonucleotides can be used together or sequentially.

The antisense oligonucleotides in accordance with this invention preferably are from about 10 to about 50 nucleotides in length (*e.g.*, 12 to 40, 14 to 30, or 15 to 25  
5 nucleotides in length). Antisense oligonucleotides that are 15 to 23 nucleotides in length are particularly useful. However, an antisense oligonucleotide containing even fewer than 10 nucleotides (for example, a portion of one of the preferred antisense oligonucleotides) is understood to be included within the present invention so long as it demonstrates the desired activity of inhibiting expression of the TRPC4 purinoreceptor.

10 An “antisense oligonucleotide” can be an oligonucleotide as described herein. The term “oligonucleotide” refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or analogs thereof. This term includes oligonucleotides composed of naturally occurring nucleotide bases, sugars and covalent internucleoside (backbone) linkages, as well as oligonucleotides having non-naturally occurring portions  
15 which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for a nucleic acid target, and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense molecules, the  
20 present invention includes other oligomeric antisense molecules, including but not limited to oligonucleotide analogs such as those described below. As is known in the art, a nucleoside is a base-sugar combination, wherein the base portion is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate  
25 group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric molecule. The respective ends of this linear polymeric structure can be further joined to form a  
30 circular structure, although linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the

internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

TRPC4 antisense oligonucleotides that are useful in the present invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages.

5 As defined herein, oligonucleotides having modified backbones include those that have a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone also can be considered to be oligonucleotides.

10 Modified oligonucleotide backbones can include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates (*e.g.*, 3'-alkylene phosphonates and chiral phosphonates), phosphinates, phosphoramidates (*e.g.*, 3'-amino phosphoramidate and aminoalkylphosphoramidates), thionophosphoramidates, thionoalkylphosphonates, 15 thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, as well as 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included. References that teach the preparation of such modified backbone oligonucleotides are provided, for example, in U.S. Patent Nos. 20 4,469,863 and 5,750,666.

TRPC4 antisense molecules with modified oligonucleotide backbones that do not include a phosphorus atom therein can have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic 25 internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide 30 backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts.

References that teach the preparation of such modified backbone oligonucleotides are provided, for example, in U.S. Patent Nos. 5,235,033 and 5,596,086.

In another embodiment, a TRPC4 antisense molecule can be an oligonucleotide analog, in which both the sugar and the internucleoside linkage (*i.e.*, the backbone) of the nucleotide units are replaced with novel groups, while the base units are maintained for hybridization with an appropriate nucleic acid target. One such oligonucleotide analog that has been shown to have excellent hybridization properties is referred to as a peptide nucleic acid (PNA). In PNA molecules, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone (*e.g.*, an aminoethylglycine backbone). The nucleotide bases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. References that teach the preparation of such modified backbone oligonucleotides are provided, for example, in Nielsen et al., 1991, *Science*, 254:1497-1500, and in U.S. Patent No. 5,539,082.

Other useful TRPC4 antisense oligonucleotides can have phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular  $\text{CH}_2\text{NHOCH}_2$ ,  $\text{CH}_2\text{N}(\text{CH}_3)\text{OCH}_2$ ,  $\text{CH}_2\text{ON}(\text{CH}_3)\text{CH}_2$ ,  $\text{CH}_2\text{N}(\text{CH}_3)\text{N}(\text{CH}_3)\text{CH}_2$ , and  $\text{ON}(\text{CH}_3)\text{CH}_2\text{CH}_2$  (wherein the native phosphodiester backbone is represented as  $\text{OPOCH}_2$ ) as taught in U.S. Patent No. 5,489,677, and the amide backbones disclosed in U.S. Patent No. 5,602,240.

Substituted sugar moieties also can be included in modified oligonucleotides. TRPC4 antisense oligonucleotides of the invention can comprise one or more of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S-, or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted  $\text{C}_1$  to  $\text{C}_{10}$  alkyl or  $\text{C}_2$  to  $\text{C}_{10}$  alkenyl and alkynyl. Useful modifications also can include  $\text{O}[(\text{CH}_2)_n\text{O}]_m\text{CH}_3$ ,  $\text{O}(\text{CH}_2)_n\text{OCH}_3$ ,  $\text{O}(\text{CH}_2)_n\text{NH}_2$ ,  $\text{O}(\text{CH}_2)_n\text{CH}_3$ ,  $\text{O}(\text{CH}_2)_n\text{ONH}_2$ , and  $\text{O}(\text{CH}_2)_n\text{ON}[(\text{C}_2)_n\text{CH}_3]_2$ , where  $n$  and  $m$  are from 1 to about 10. In addition, oligonucleotides can comprise one of the following at the 2' position:  $\text{C}_1$  to  $\text{C}_{10}$  lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH,  $\text{SCH}_3$ , OCN, Cl, Br, CN,  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  $\text{SOCH}_3$ ,  $\text{SO}_2\text{CH}_3$ ,  $\text{ONO}_2$ ,  $\text{NO}_2$ ,  $\text{N}_3$ ,  $\text{NH}_2$ , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, groups for improving the pharmacokinetic or

pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. Other useful modifications include an alkoxyalkoxy group, *e.g.*, 2'-methoxyethoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>), a dimethylaminooxyethoxy group (2'-O(CH<sub>2</sub>)<sub>2</sub>ON(CH<sub>3</sub>)<sub>2</sub>), or a dimethylamino-ethoxyethoxy group (2'-OCH<sub>2</sub>OCH<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>).

5 Other modifications can include 2'-methoxy (2'-OCH<sub>3</sub>), 2'-aminopropoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>), or 2'-fluoro (2'-F). Similar modifications also can be made at other positions within the oligonucleotide, such as the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides, and the 5' position of the 5' terminal nucleotide. Oligonucleotides also can have sugar mimetics such as cyclobutyl moieties in

10 place of the pentofuranosyl group. References that teach the preparation of such substituted sugar moieties include U.S. Patent Nos. 4,981,957 and 5,359,044.

Useful TRPC4 antisense oligonucleotides also can include nucleotide base modifications or substitutions. As used herein, "unmodified" or "natural" nucleotide bases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases

15 thymine (T), cytosine (C), and uracil (U). Modified nucleotide bases can include other synthetic and natural nucleotide bases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-

20 propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-

25 deazaadenine. Other useful nucleotide bases include those disclosed, for example, in U.S. Patent No. 3,687,808.

Certain nucleotide base substitutions can be particularly useful for increasing the binding affinity of the antisense oligonucleotides of the invention. For example, 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by

30 0.6 to 1.2°C (Sanghvi et al., eds, *Antisense Research and Applications*, pp. 276-278, CRC Press, Boca Raton, FL, 1993). Other useful nucleotide base substitutions include 5-

substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines such as 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.

Antisense oligonucleotides of the invention also can be modified by chemical linkage to one or more moieties or conjugates that enhance the activity, cellular  
5 distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties (*e.g.*, a cholesterol moiety); cholic acid; a thioether moiety (*e.g.*, hexyl-S-tritylthiol); a thiocholesterol moiety; an aliphatic chain (*e.g.*, dodecandiol or undecyl residues); a phospholipid moiety (*e.g.*, di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate); a polyamine or a  
10 polyethylene glycol chain; adamantane acetic acid; a palmityl moiety; or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety. The preparation of such oligonucleotide conjugates is disclosed in, for example, U.S. Patent Nos. 5,218,105 and 5,214,136.

It is not necessary for all nucleotide base positions in a given antisense  
15 oligonucleotide to be uniformly modified. More than one of the aforementioned modifications can be incorporated into a single oligonucleotide or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense oligonucleotides that are chimeric oligonucleotides. "Chimeric" antisense oligonucleotides can contain two or more chemically distinct regions, each made up of at  
20 least one monomer unit (*e.g.*, a nucleotide in the case of an oligonucleotide). Chimeric oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer, for example, increased resistance to nuclease degradation, increased cellular uptake, and/or increased affinity for the target nucleic acid. For example, a region of a chimeric oligonucleotide can serve as a substrate for an enzyme  
25 such as RNase H, which is capable of cleaving the RNA strand of an RNA:DNA duplex such as that formed between a target mRNA and an antisense oligonucleotide. Cleavage of such a duplex by RNase H, therefore, can greatly enhance the effectiveness of an antisense oligonucleotide.

Antisense molecules in accordance with the invention can include enzymatic  
30 ribonucleic acid molecules that can cleave other ribonucleic acid molecules (ribozymes). Antisense technologies involving ribozymes have shown great utility in research,

diagnostic and therapeutic contexts. Methods for designing and using ribozymes are well known, and have been extensively described. Ribozymes in general are described, for example, in U.S. Patent Nos. 5,254,678; 5,496,698; 5,525,468; and 5,616,459. U.S. Patent Nos. 5,874,414 and 6,015,794 describe trans-splicing ribozymes. Hairpin ribozymes are described, for example, in U.S. Patent Nos. 5,631,115; 5,631,359; 5,646,020; 5,837,855 and 6,022,962. U.S. Patent No. 6,307,041 describes circular, hairpin, circular/hairpin, lariat, and hairpin-lariat hammerhead ribozymes. Ribozymes can include deoxyribonucleotides (see, *e.g.*, U.S. Patent Nos. 5,652,094; 6,096,715 and 6,140,491). Such ribozymes are often referred to as (nucleozymes). Ribozymes can include modified ribonucleotides. Base-modified enzymatic nucleic acids are described, for example, in U.S. Patent Nos. 5,672,511; 5,767,263; 5,879,938 and 5,891,684. U.S. Patent No. 6,204,027 describes ribozymes having 2'-O substituted nucleotides in the flanking sequences. U.S. Patent No. 5,545,729 describes stabilized ribozyme analogs. Other ribozymes having specialized properties have been described, for example, in U.S. Patent No. 5,942,395 (describing chimeric ribozymes that include a snoRNA stabilizing motif), U.S. Patent Nos. 6,265,167 and 5,908,779 (describing nuclear ribozymes), U.S. Patent No. 5,994,124 (describing ribozyme-snRNA chimeric molecules having a catalytic activity for nuclear RNAs); and U.S. Patent No. 5,650,502 (describing ribozyme analogs with rigid non-nucleotidic linkers).

The TRPC4 antisense oligonucleotides of the invention are synthesized *in vitro* and do not include antisense compositions of biological origin, except for oligonucleotides that comprise the subject antisense oligonucleotides and have been purified from or isolated from biological material. Antisense oligonucleotides used in accordance with this invention can be conveniently produced through the well-known technique of solid phase synthesis. Equipment for such synthesis is commercially available from several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art additionally or alternatively can be employed. Similar techniques also can be used to prepare modified oligonucleotides such as phosphorothioates or alkylated derivatives.

30

*Antisense Preparations and Methods for Use*

The antisense oligonucleotides of the invention are useful for research (*e.g.*, in developing assays to identify small molecule therapeutics), diagnostics, and for therapeutic use. For example, assays based on hybridization of antisense oligonucleotides to nucleic acids encoding TRPC4 can be used to evaluate levels of TRPC4 in a tissue sample. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding TRPC4 can be detected by means known in the art. Such means can include conjugation of an enzyme to the antisense oligonucleotide, radiolabeling of the antisense oligonucleotide, or any other suitable means of detection.

Those of skill in the art can harness the specificity and sensitivity of antisense technology for therapeutic use. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals, including humans. For therapeutic methods, the cells or tissues are typically within a vertebrate (*e.g.*, a mammal such as a human).

The invention provides therapeutic methods for treating conditions involving abnormal expression (*e.g.*, over-production) or altered function of the TRPC4 purinoreceptor. By these methods, antisense oligonucleotides in accordance with the invention are administered to a subject (*e.g.*, a human) suspected of having a disease or condition (*e.g.*, chronic pain or irritable bowel syndrome) that can be alleviated by modulating the expression of TRPC4. Typically, one or more antisense oligonucleotides can be administered to a subject suspected of having a disease or condition associated with the expression of TRPC4. The antisense oligonucleotide can be in a pharmaceutically acceptable carrier or diluent, and can be administered in amounts and for periods of time that will vary depending upon the nature of the particular disease, its severity, and the subject's overall condition. Typically, the antisense oligonucleotide is administered in an inhibitory amount (*i.e.*, in an amount that is effective for inhibiting the production of TRPC4 in the cells or tissues contacted by the antisense oligonucleotides). The antisense oligonucleotides and methods of the invention also can be used prophylactically, *e.g.*, to minimize pain in a subject that exhibits abnormal expression of TRPC4 or altered TRPC4 function.

The ability of a TRPC4 antisense oligonucleotide to inhibit expression and/or production of TRPC4 can be assessed, for example, by measuring levels of TRPC4 mRNA or protein in a subject before and after treatment. Methods for measuring mRNA and protein levels in tissues or biological samples are known in the art. If the subject is a research animal, for example, TRPC4 levels in the brain can be assessed by *in situ* hybridization or immunostaining following euthanasia. Indirect methods can be used to evaluate the effectiveness of TRPC4 antisense oligonucleotides in live subjects. For example, reduced expression of TRPC4 can be inferred from reduced sensitivity to painful stimuli. As described in the Examples below, animal models can be used to study the development, maintenance, and relief of chronic neuropathic or inflammatory pain. Animals subjected to these models generally develop thermal hyperalgesia (*i.e.*, an increased response to a stimulus that is normally painful) and/or allodynia (*i.e.*, pain due to a stimulus that is not normally painful). Sensitivity to mechanical and thermal stimuli can be assessed (see Bennett, *Methods in Pain Research*, pp. 67-91, Kruger, Ed., 2001) to evaluate the effectiveness of TRPC4 antisense treatment.

Methods for formulating and subsequently administering therapeutic compositions are well known to those skilled in the art. Dosing is generally dependent on the severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Persons of ordinary skill in the art routinely determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages can vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC<sub>50</sub> values found to be effective in *in vitro* and *in vivo* animal models. Typically, dosage is from 0.01 µg to 100 g per kg of body weight, and may be given once or more daily, weekly, or even less often. Dosage and dosing schedules vary depending on route of administration (*e.g.*, systemic doses typically are greater than intrathecal or epidural doses). Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state.

The present invention provides pharmaceutical compositions and formulations that include the TRPC4 antisense oligonucleotides of the invention. TRPC4 antisense

oligonucleotides therefore can be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecular structures, or mixtures of oligonucleotides such as, for example, liposomes, receptor targeted molecules, or oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption.

5           A “pharmaceutically acceptable carrier” (also referred to herein as an “excipient”) is a pharmaceutically acceptable solvent, suspending agent, or any other pharmacologically inert vehicle for delivering one or more therapeutic molecules (*e.g.*, TRPC4 antisense oligonucleotides) to a subject. Pharmaceutically acceptable carriers can be liquid or solid, and can be selected with the planned manner of administration in mind  
10 so as to provide for the desired bulk, consistency, and other pertinent transport and chemical properties, when combined with one or more of therapeutic molecules and any other components of a given pharmaceutical composition. Typical pharmaceutically acceptable carriers that do not deleteriously react with nucleic acids include, by way of example and not limitation: water; saline solution; binding agents (*e.g.*,  
15 polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (*e.g.*, lactose and other sugars, gelatin, or calcium sulfate); lubricants (*e.g.*, starch, polyethylene glycol, or sodium acetate); disintegrates (*e.g.*, starch or sodium starch glycolate); and wetting agents (*e.g.*, sodium lauryl sulfate).

The pharmaceutical compositions of the present invention can be administered by  
20 a number of methods depending upon whether local or systemic treatment is desired and depending upon the area to be treated. Administration can be, for example, topical (*e.g.*, transdermal, ophthalmic, or intranasal); pulmonary (*e.g.*, by inhalation or insufflation of powders or aerosols); oral; or parenteral (*e.g.*, by subcutaneous, intrathecal, intraventricular, intramuscular, or intraperitoneal injection, or by intravenous drip).  
25 Administration can be rapid (*e.g.*, by injection) or can occur over a period of time (*e.g.*, by slow infusion or administration of slow release formulations). For treating tissues in the central nervous system, antisense oligonucleotides can be administered by injection or infusion into the cerebrospinal fluid, preferably with one or more agents capable of promoting penetration of the antisense oligonucleotide across the blood-brain barrier.

30           Formulations for topical administration of antisense oligonucleotides include, for example, sterile and non-sterile aqueous solutions, non-aqueous solutions in common

solvents such as alcohols, or solutions in liquid or solid oil bases. Such solutions also can contain buffers, diluents and other suitable additives. Pharmaceutical compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Coated  
5 condoms, gloves and the like also may be useful. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

Compositions and formulations for oral administration include, for example, powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Such compositions also can incorporate thickeners, flavoring agents,  
10 diluents, emulsifiers, dispersing aids, or binders. Oligonucleotides with at least one 2'-O-methoxyethyl modification (described above) may be particularly useful for oral administration.

Compositions and formulations for parenteral, intrathecal or intraventricular administration can include sterile aqueous solutions, which also can contain buffers,  
15 diluents and other suitable additives (*e.g.*, penetration enhancers, carrier molecules and other pharmaceutically acceptable carriers).

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, aqueous suspensions, and liposome-containing formulations. These compositions can be generated from a variety of components that include, for  
20 example, preformed liquids, self-emulsifying solids and self-emulsifying semisolids. Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other; in general, emulsions are either of the water-in-oil (w/o) or oil-in-water (o/w) variety. Emulsion formulations have been widely used for oral delivery of therapeutics due to their ease of formulation and efficacy of  
25 solubilization, absorption, and bioavailability.

Liposomes are vesicles that have a membrane formed from a lipophilic material and an aqueous interior that can contain the antisense composition to be delivered. Liposomes can be particularly useful due to their specificity and the duration of action they offer from the standpoint of drug delivery. Liposome compositions can be formed,  
30 for example, from phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dimyristoyl phosphatidylglycerol, or dioleoyl

phosphatidylethanolamine. Numerous lipophilic agents are commercially available, including Lipofectin<sup>®</sup> (Invitrogen/Life Technologies, Carlsbad, CA) and Effectene<sup>™</sup> (Qiagen, Valencia, CA).

The TRPC4 antisense oligonucleotides of the invention further encompass any  
5 pharmaceutically acceptable salts, esters, or salts of such esters, or any other molecule  
which, upon administration to an animal including a human, is capable of providing  
(directly or indirectly) the biologically active metabolite or residue thereof. Accordingly,  
for example, the invention provides pharmaceutically acceptable salts of TRPC4  
antisense oligonucleotides, prodrugs and pharmaceutically acceptable salts of such  
10 prodrugs, and other bioequivalents. The term “prodrug” indicates a therapeutic agent that  
is prepared in an inactive form and is converted to an active form (*i.e.*, drug) within the  
body or cells thereof by the action of endogenous enzymes or other chemicals and/or  
conditions. The term “pharmaceutically acceptable salts” refers to physiologically and  
pharmaceutically acceptable salts of the oligonucleotides of the invention (*i.e.*, salts that  
15 retain the desired biological activity of the parent oligonucleotide without imparting  
undesired toxicological effects). Examples of pharmaceutically acceptable salts of  
oligonucleotides include, but are not limited to, salts formed with cations (*e.g.*, sodium,  
potassium, calcium, or polyamines such as spermine); acid addition salts formed with  
inorganic acids (*e.g.*, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid,  
20 or nitric acid); salts formed with organic acids (*e.g.*, acetic acid, citric acid, oxalic acid,  
palmitic acid, or fumaric acid); and salts formed from elemental anions (*e.g.*, chlorine,  
bromine, and iodine).

Pharmaceutical compositions containing the antisense oligonucleotides of the  
present invention also can incorporate penetration enhancers that promote the efficient  
25 delivery of nucleic acids, particularly oligonucleotides, to the skin of animals.  
Penetration enhancers can enhance the diffusion of both lipophilic and non-lipophilic  
drugs across cell membranes. Penetration enhancers can be classified as belonging to one  
of five broad categories, *i.e.*, surfactants (*e.g.*, sodium lauryl sulfate, polyoxyethylene-9-  
lauryl ether and polyoxyethylene-20-cetyl ether); fatty acids (*e.g.*, oleic acid, lauric acid,  
30 myristic acid, palmitic acid, and stearic acid); bile salts (*e.g.*, cholic acid, dehydrocholic  
acid, and deoxycholic acid); chelating agents (*e.g.*, disodium ethylenediaminetetraacetate,

citric acid, and salicylates); and non-chelating non-surfactants (*e.g.*, unsaturated cyclic ureas).

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense oligonucleotides and (b) one or more other agents  
5 that function by a non-antisense mechanism. For example, anti-inflammatory drugs, including but not limited to non-steroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, can be included in compositions of the invention. Other non-antisense agents (*e.g.*, chemotherapeutic agents) are also within the scope of this invention. Such  
10 combined molecules can be used together or sequentially.

The antisense compositions of the present invention additionally can contain other adjunct components conventionally found in pharmaceutical compositions. Thus, the compositions also can include compatible, pharmaceutically active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or  
15 additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. Furthermore, the composition can be mixed with auxiliary agents, *e.g.*, lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings,  
20 and aromatic substances. When added, however, such materials should not unduly interfere with the biological activities of the antisense components within the compositions of the present invention. The formulations can be sterilized and, if desired, and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

25 The pharmaceutical formulations of the present invention, which can be presented conveniently in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients (*e.g.*, the TRPC4 antisense oligonucleotides of the invention) with the desired pharmaceutical carrier(s) or excipient(s). Typically, the  
30 formulations can be prepared by uniformly and bringing the active ingredients into intimate association with liquid carriers or finely divided solid carriers or both, and then,

if necessary, shaping the product. Formulations can be sterilized if desired, provided that the method of sterilization does not interfere with the effectiveness of the antisense oligonucleotide contained in the formulation.

The compositions of the present invention can be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention also can be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions further can contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol, and/or dextran. Suspensions also can contain stabilizers.

#### *Nucleic Acid Constructs*

Nucleic acid constructs (*e.g.*, a plasmid vector) are capable of transporting a nucleic acid into a host cell. Suitable host cells include prokaryotic or eukaryotic cells (*e.g.*, bacterial cells such as *E. coli*, insect cells, yeast cells, and mammalian cells). Some constructs are capable of autonomously replicating in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell and are replicated with the host genome.

Nucleic acid constructs can be, for example, plasmid vectors or viral vectors (*e.g.*, replication defective retroviruses, adenoviruses, and adeno-associated viruses). Nucleic acid constructs include one or more regulatory sequences operably linked to the nucleic acid of interest (*e.g.*, a nucleic acid encoding a transcript that specifically hybridizes to a TRPC4 mRNA in its native form). With respect to regulatory elements, "operably linked" means that the regulatory sequence and the nucleic acid of interest are positioned such that nucleotide sequence is transcribed (*e.g.*, when the vector is introduced into the host cell).

Regulatory sequences include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). See, *e.g.*, Goeddel, *Gene Expression Technology: Methods in Enzymology*, 185, Academic Press, San Diego, CA, 1990.

Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cells and that direct expression of the nucleotide sequence only in certain host cells (*e.g.*, cell type or tissue-specific regulatory sequences).

5 *Articles of Manufacture*

Antisense oligonucleotides of the invention can be combined with packaging material and sold as kits for reducing TRPC4 expression. Components and methods for producing articles of manufacture such as kits are well known. An article of manufacture may combine one or more of the antisense oligonucleotides set out in the above sections.

10 In addition, the article of manufacture further may include buffers, hybridization reagents, or other control reagents for reducing or monitoring reduced TRPC4 expression. Instructions describing how the antisense oligonucleotides are effective for reducing TRPC4 expression can be included in such kits.

The invention will be further described in the following examples, which do not  
15 limit the scope of the invention described in the claims.

## EXAMPLES

### Example 1 – Materials and Methods

#### *Determination of Accessible Sites Within the TRPC4 mRNA and Design of TRPC4*

20 *Antisense Oligonucleotides*

Accessible regions of rat TRPC4 mRNA (as determined by the RiboTAG™ method) are shown in Table 1.

Table 1

25 Accessible sequences within rat TRPC4 mRNA

Start	End
43	86
325	342
438	461
624	641
928	949

1123	1132
1190	1209
1433	1450
1806	1824
2313	2331
2499	2512
2855	2875

---

*Methods for Evaluating Pain in Rats Treated with Antisense TRPC4*

Two different models of chronic pain were used to evaluate the effects of TRPC4 knock-down by intrathecally administered antisense oligonucleotides. Both models  
 5 included the following six steps (described in greater detail below):

- (1) spinal catheterization;
- (2) nociceptive testing (baseline);
- (3) induction of chronic neuropathic or inflammatory pain;
- (4) nociceptive testing (post-injury);
- 10 (5) antisense injection; and
- (6) nociceptive testing (post-treatment).

Spinal Catheterization: Male Sprague Dawley rats weighing between 200 and 250 g were obtained from Harlan (Indianapolis, IN). Rats were deeply anesthetized with a mixture containing 75 mg/kg ketamine, 5 mg/kg xylazine, and 1 mg/kg acepromazine, and a  
 15 catheter (8.5 cm; PE-10) was passed to the lumbosacral intrathecal space through an incision in the dura over the atlantooccipital joint. Following surgery, animals were kept on a warming blanket and were periodically turned and carefully observed until completely recovered from anesthesia. Animals were allowed to recover for at least 3 days before being subjected to models of chronic pain.

20 Mechanical Nociceptive Testing: Baseline, post-injury, and post-treatment values for mechanical sensitivity were evaluated with calibrated monofilaments (von Frey filaments) according to the up-down method (Chaplan et al., 1994, *J. Neurosci. Methods*, 53:55-63). Animals were placed on a wire mesh platform and allowed to acclimate to their surroundings for a minimum of 10 minutes before testing. Filaments of increasing

force were sequentially applied to the plantar surface of the paw just to the point of bending, and held for three seconds. The behavioral endpoint of the stimulus (achieved when the stimulus was of sufficient force) was the point at which the animal would lick, withdraw and/or shake the paw. The force or pressure required to cause a paw withdrawal was recorded as a measure of threshold to noxious mechanical stimuli for each hind-paw. The mean and standard error of the mean (SEM) were determined for each animal in each treatment group. The data were analyzed using repeated measures ANOVA followed by the Bonferonni post-hoc test. Since this stimulus is normally not considered painful and rats do not normally respond to filaments in the range selected, significant injury-induced increases in responsiveness in this test were interpreted as a measure of mechanical allodynia.

Thermal Nociceptive Testing: Baseline, post-injury, and post-treatment thermal sensitivities were determined by measuring withdrawal latencies in response to radiant heat stimuli delivered to the plantar surface of the hind-paws (Hargreaves et al., 1988, *Pain*, 32:77-88). Animals were placed on a plexiglass platform and allowed to acclimate for a minimum of 10 minutes. A radiant heat source was directed to the plantar surface, and the time to withdrawal was measured. For each paw, the withdrawal latency was determined by averaging three measurements separated by at least 5 minutes. The heating device was set to automatically shut off after a programmed period of time to avoid damage to the skin of unresponsive animals. The data were analyzed using repeated measures ANOVA followed by the Bonferonni post-hoc test. Significant injury-induced increases in thermal response latencies were considered to be a measure of thermal hyperalgesia since the stimulus is normally in the noxious range.

Induction of Chronic Neuropathic Pain: The Spinal Nerve Ligation (SNL) model (Kim & Chung, 1992, *Pain*, 50:355-63) was used to induce chronic neuropathic pain. Rats were anesthetized with isoflurane, the L5 transverse process was removed, and the L5 and L6 spinal nerves were tightly ligated with 6-0 silk suture. The wound was then closed with internal sutures and external staples. Control animals received a sham surgery consisting of removing the transverse process and exposing the L5 spinal nerve without ligating. All operations were performed on the left side.

Induction of Chronic Inflammation: The complete Freund's adjuvant (CFA) model of

chronic peripheral inflammation was utilized (see, for example, Hylden et al., 1989, Pain, 37:229-43). Rats under light anesthesia received an injection of CFA (75  $\mu$ l) into the left hindpaw using a sterile 1.0 ml syringe. A separate population of control rats was subjected to unilateral injection of saline.

5 Antisense Design and Injection: Antisense oligonucleotides were commercially synthesized (Midland Certified Reagent Company, Midland, TX) and purified prior to injection. Oligonucleotides were dissolved in dH<sub>2</sub>O and delivered into the intrathecal space in a volume of 5  $\mu$ l per injection as previously described (see, for example, Bilsky et al., 1996, *Neurosci. Lett.*, 220:155-158; Bilsky et al., 1996, *J. Pharmacol. Exp. Ther.*, 10 277:491-501; and Vanderah et al., 1994, *Neuroreport.*, 5:2601-2605). Antisense oligonucleotides were administered twice daily for 3 to 4 days, beginning on the afternoon following post-injury (baseline) nociceptive testing. Antisense oligonucleotides that were used included the sequence: GAT AGG CGT GAT GTC TGG G (SEQ ID NO:3), which specifically hybridize to nucleotides 439 through 457 of SEQ 15 ID NO:1.

#### *Immunolocalization of TRPC4*

Human spinal cord and dorsal root ganglia were obtained post-mortem and immersion-fixed in 4% paraformaldehyde for 4 hours or overnight, respectively. After 20 fixation, the tissue was washed in phosphate buffered saline (PBS) for 2-3 days and stored in 10% sucrose cryoprotectant solution. The tissue was cut in a cryostat into 14  $\mu$ m section. Slide-mounted cryostat sections were incubated in blocking buffer for 1 hour at room temperature, followed by primary antisera (affinity purified guinea pig anti-TRPC4, 1:5000) overnight at 4°C. The staining was visualized using cyanine 3.18- 25 conjugated secondary antisera (Jackson ImmunoResearch, West Grove, CA). For absorption control, the primary antisera were incubated with the corresponding peptide antigen (10  $\mu$ g/ml) prior to application to tissue sections.

In spinal cord, the staining was localized in the superficial laminae of the dorsal horn, which is involved in processing of pain-related signals. In dorsal root ganglia, 30 TRPC4 immunoreactivity was present in both small and large sensory neurons. However, the staining intensity appeared higher in small neurons, the majority of which were likely

to be nociceptors. The distribution of TRPC4 in human spinal cord and sensory neurons is consistent with a possible role for this protein in pain signaling.

5 Example 2 – Antisense Knockdown of TRPC4 in Rat Spinal Cord Supports a Role in Chronic Neuropathic and Inflammatory Pain

Antisense oligonucleotides were designed by the RiboTAG™ method and used to evaluate the role of TRPC4 in chronic pain. Thermal (radiant heat) and mechanical (von Frey) pain thresholds were obtained before and after induction of chronic pain (neuropathic or inflammatory, as described in Example 1, above). Antisense  
10 oligonucleotides (45 µg) or vehicle controls were delivered twice daily for 3 to 4 days, and thermal and mechanical thresholds were reassessed.

Figure 3 demonstrates that treatment with a TRPC4 antisense oligonucleotide reversed the effects of chronic neuropathic pain. Normal rats responded to a noxious heat stimulus with an average latency of 20 seconds. Following nerve injury, the response  
15 time decreased to about 10 seconds (Figure 3A). Such a drop is analogous to the abnormal pain sensitivity observed in human patients suffering from chronic pain. Following three days of TRPC4 antisense treatment, there was a significant dose-related reversal of the nerve injury-induced hypersensitivity. Figure 3B shows that TRPC4 antisense treatment also increased the tolerance to noxious mechanical stimuli. Normal  
20 animals rarely respond to stimuli of less than 15 g. Following SNL, however, animals withdrew from stimuli of only a few grams. TRPC4 antisense treatment reversed this hypersensitivity in a dose-dependent manner. The thermal and mechanical data are combined in Figure 3C, which depicts the results as the percentage reversal of nerve injury-induced hypersensitivity as a function of antisense dose.

As shown in Figure 4A and Figure 4B, animals subjected to a model of  
25 inflammation become significantly more sensitive to thermal and mechanical stimuli (as evidenced by the decreases in their response thresholds compared to pre-inflammation baseline ('Baseline') and uninflamed controls). Following three days of antisense treatment, there was a significant reduction in inflammation-induced hypersensitivity to  
30 both thermal mechanical stimuli ('Treated').

Example 3 – Quantitative TaqMan RT-PCR Analysis of TRPC4 After Antisense Treatment

Quantitative PCR method is used to evaluate TRPC4 mRNA levels in control animals, and in animals with a chronic inflammation in one of the hindpaws, treated with TRPC4 antisense or a mismatch. Treatment with antisense reduces the level of TRPC4-mRNA in both inflamed and control animals.

TaqMan PCR is carried out using an ABI 7700 sequence detector (Perkin Elmer) on the cDNA samples. TaqMan primer and probe sets are designed from sequences in the GeneBank database using Primer Express (Perkin Elmer).

10

### **OTHER EMBODIMENTS**

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

15

**WHAT IS CLAIMED IS:**

1. An isolated antisense oligonucleotide consisting essentially of 10 to 50 nucleotides, wherein said oligonucleotide specifically hybridizes within an accessible region of TRPC4 mRNA, said region defined by nucleotides 43 through 86, 325 through 342, 438 through 461, 624 through 641, 928 through 949, 1123 through 1132, 1190 through 1209, 1433 through 1450, 1806 through 1824, 2313 through 2331, 2499 through 2512, or 2855 through 2875 of SEQ ID NO:1, and wherein said oligonucleotide inhibits the production of TRPC4.
2. A composition comprising the isolated antisense oligonucleotide of claim 1.
3. The composition of claim 2, wherein said composition comprises a plurality of isolated antisense oligonucleotides, wherein each antisense oligonucleotide specifically hybridizes within a different accessible region.
4. A nucleic acid construct comprising a regulatory element operably linked to a nucleic acid encoding a transcript, wherein said transcript specifically hybridizes within one or more accessible regions of TRPC4 mRNA in its native form.
5. A host cell comprising the nucleic acid construct of claim 4.
6. A method of decreasing production of TRPC4 in cells or tissues, comprising contacting said cells or tissues with an antisense oligonucleotide that specifically hybridizes within an accessible region of TRPC4.
7. An isolated antisense oligonucleotide that specifically hybridizes within an accessible region of TRPC4 mRNA in its native form, wherein said antisense oligonucleotide inhibits the production of TRPC4.

8. A method for modulating pain in a mammal, said method comprising administering the isolated antisense oligonucleotide of claim 7 to said mammal.
9. A method of identifying a compound that modulates pain in a mammal,  
5 the method comprising:  
contacting cells comprising a TRPC4 nucleic acid with a compound; and  
detecting the amount of TRPC4 RNA or TRPC4 polypeptide in or secreted  
from said cell,  
wherein a difference in the amount of TRPC4 RNA or TRPC4 polypeptide in the  
10 presence of said compound compared to the amount of TRPC4 RNA or TRPC4  
polypeptide produced in the absence of said compound is an indication that said  
compound modulates pain in said mammal.
10. The method of claim 9, wherein the amount of said TRPC4 RNA is  
15 determined by Northern blotting.
11. The method of claim 9, wherein the amount of said TRPC4 polypeptide is  
determined by Western blotting.
12. The method of claim 9, wherein said compound is an antisense  
20 oligonucleotide that specifically hybridizes within an accessible region of TRPC4 mRNA  
in its native form, wherein said antisense oligonucleotide inhibits production of TRPC4.
13. A method for modulating pain in a mammal, said method comprising  
25 administering a compound to said mammal, wherein said compound modulates the  
expression of TRPC4.
14. The method of claim 13, wherein said compound is an antisense  
oligonucleotide that specifically hybridizes within an accessible region of TRPC4 mRNA  
30 in its native form, wherein said antisense oligonucleotide inhibits production of TRPC4.

15. The method of claim 13, wherein said pain is from diabetic neuropathy, postherpetic neuralgia, fibromyalgia, surgery, or chronic back pain.

```

1 gactagcatg gcctgaagca tggctcagtt ctattacaaa cgaaatgtca acgcccccta
61 ccgagaccgc atcccactga ggatcgtcag ggcagaatct gaactctcac catcagagaa
121 agcctacttg aatgccgtgg aaaaggggga ctatgcaagc gtcaagaaat ctctggagga
181 agccgagatt tattttaaaa tcaacattaa ctgcattgac ccccttggga ggactgctct
241 tctcattgcc attgaaaatg agaacctgga gctgattgaa ctggttggta gtttcaatgt
301 ctatgttggc gatgcgctac ttcacgcoat caggaaagag gtggttggag cctggagct
361 actgctgaac cacaaaaagc ccagcggaga gaagcagggtg cctccatcc tccttgacaa
421 acagtctctt gaattcacc cagacatcac gcctatcatc ttggctgcac atacaaataa
481 ttatgagata atcaaaactt tggccagaa ggggtgtctg gtgccagac cccacgaggt
541 ccgctgtaac tgtgttgagt gtgtctccag ctgagacgtg gacagcctca ggcactcacg
601 gtccaggctc aacatctaca aggccttggc cagccctctg ctattggcg tgtcaagtga
661 agaccctttc ctcaccgctc ttcagttaag ctgggagctg caagaactga gtaaggtgga
721 gaatgaattc aagtcggagt atgaggagct gtctagacag tgcaaacagt ttgctaagga
781 cctcctagat cagacacgga gttccagaga gctggaaatc attcttaatt accgtgatga
841 caatagcctg atcgaagaac agagtggaaa tgatcttgcg aggctaaaat tagccattaa
901 gtaccgtcaa aaagagttt ttgctcagcc caactgccag cagctgcttg ctctccgctg
961 gtacgatgag ttcccaggct ggaggagaag aactggggcg gtgaagatgg tgacatgttt
1021 cataatagga ctactcttcc cgtcttctc cgtgtgctac ctgtagctc ccaaagccc
1081 acttggactg ttcacagaa agccatttat caagtttatc tgccacacag cctcctatct
1141 gacctttttg tttctgctgc tgcagcctc tcagcacatc gacaggctcag acttgaacag
1201 gaaggtcca ccaccaacca tcgtggagtg gatgatatta ccgtgggtcc tgggttttat
1261 atggggagag attaaacaga tgtgggatgg cggactccag gattacatcc acgactgggtg
1321 gaatctaatt gacttttga tgaactcctt gtatctggcg acaatctcct tgaagattgt
1381 cgcatttgta aagtacagt ctctgaacc acgggaatca tgggacatgt ggcacccac
1441 cctgggtggc gaggctttat tcgcaattgc aaacatctc agttccctcc gcctgatctc
1501 tctgttcact gccaatctc acctggggcc tctgcagata tctctgggaa gaatgctcct
1561 ggacatccta aagttcttat tcatatactg cctcgtgctg cttagctttt caaatggcct
1621 aatcaactg tacttctact atgaagaaac gaaggggtta agctgcaaag gcatacgggtg
1681 cgaaaaacag aacaacgct tctccacgct atttgagact ctacagtccc tgttttggtc
1741 aatatttggg ctcatcaatc tctatgttac caatgtcaaa gccagcatg agttcactga
1801 tttgttggg gccaccatgt ttggcacata taacgtcatc tctctggttg tccctctgaa
1861 catgctgatc gctatgatga ataattctta ccaactaatt gccagcaag cagatagaa
1921 gtggaaattt gctcgaaca agctttggat gagctacttt gaagaaggg gtaccctgcc
1981 tacaccttc aatgtcatc caagcccaa gtccctgtgg tacctggtca agtggatatg
2041 gacacactta tgaagaaaa aatgagaag aaagccagaa agctttggga caatcgggctg
2101 gcgtgctgct gataacttga gaaggcatca ccaataccaa gaggtgatga ggaatctggt
2161 gaagcggtag gtggcagcca tgatcagaga ggcaaaaact gaagaaggct tgacagagga
2221 gaatgttaag gaactaaagc aagacattc tagcttccgc ttcgaagttc tgggattgct
2281 ccggggaagc aagctctcaa caatacagtc agccaacgca gcgagttcag ccagctccgc
2341 ggactccgat gagaagagcc acagcgaagg taatggcaag gacaagagaa agaactctcag
2401 cctctttgat ttaaccactc tgatccacc gcggtcggca gtattgctc ccgagagaca
2461 taacctaagc aatggttctg ccctggtggt gcaggagccg cccagggaga agcagaggaa
2521 agtgaatfff gtggctgata tcaaaaactt cgggttattt catagacggt caaagcaaaa
2581 tgctgctgag caaaacgcaa accaaatctt ctctgtttca gaagaaatta ctctgcaaca
2641 ggcggcagga gcacttgaga gaaatatcca actggaatcc aaaggattag cttcacgggg
2701 tgaccgcagc attcctggct tcaatgaaca gtgtgtgcta gtagaccata gagaaaggaa
2761 tacggacact ttgggtttac aggtaggcaa gagagtgtgc tctccttca agtcggagaa
2821 ggtgggtggt gaagacaccg tccctattat accaaaggag aaacacgccc aggagggaga
2881 ctcaagcata gattatgatt taagcccac ggacacagtt gccatgaag attatgtgac
2941 cagcagattg tgacaactg gagaaggagt gttaccata cctatacata ttttccatag
3001 tgctctgggc ag

```

Figure 1

```

1 gctttcagag catcctcact cgcgccagtt cggtgccagc tgcgtgggct ccagcttcga
61 tcgttttccct tggaatgctc caaaactcag cagcgactaa gggaattcca ttggaatttg
121 cggggcgtgc tctcaccctc cacggcacc ggcgcgtcag tcctcggatc coactcctc
181 agcccgaaga ttgcaacttt gcagagacga agaaatagca tggcatgaaa tatggctcag
241 ttctattaca aaagaaatgt taatgctccc tatagagacc gcatccctct aaggtagta
301 agagcagaat cagaactctc gccatcagaa aaagcctact tgaatgctgt ggaaaaggga
361 gattatgcca gtgtcaagaa atccctagag gaagctgaaa tttattttaa aatcaatatt
421 aattgcattg atcctctcgg aagaactgct ctctcattg caattgaaaa tgagaacttg
481 gagctcatcg aactactctt aagctttaat gtctatgttg gagatgctct attacatgct
541 atcagaaaag aagtcgtcgg agctgttgag ctgttattga accacaaaaa acctagtggg
601 gaaaaacagg tgctcctat actccttgat aagcagttct ctgaattcac tccagacatt
661 acaccaatca ttttggcagc ccatacaaat aattatgaga taataaaact cttggttcag
721 aaaggagtct cagtgcctcg accccacgag gtccgctgta actgtgtgga atgctgtctc
781 agttcagatg tggacagcct ccgtcactca cgctccagac tcaacatcta caaggccttg
841 gccagtcctt ctctcattgc actgtcaagc gaagatcctt ttctcacagc ctttcagtta
901 agttgggaac ttcaggaact gagcaagggt gaaaatgaat tcaagtcgga gtatgaagag
961 ctgtcacggc agtgcaaaca atttgctaag gacactactg atcagacgag aagttccaga
1021 gaactggaaa tcattcttaa ttaccgagat gacaatagtc tcatagaaga acaaagtggg
1081 aatgatcttg caagactaaa attggccatt aagtaccgtc aaaaagagt tgttgcccag
1141 cccaattgtc aacagctgct ggcactctcg tggtagatg agtttccagg ctggaggaga
1201 agacactggg cagtgaagat ggtgacatgt tccataatag gacttctttt tctgtcttc
1261 tctgtgtgct acctgatagc tcccaaaagc ccacttggac tgttcatcag gaagccattt
1321 atcaagttta tctgccacac agcctcctat ttgacttttt tgttctgct gctgcttgcc
1381 tctcagcaca tcgacaggtc agacttgaac aggcaaggtc caccaccaac catcgtcgag
1441 tggatgatat taccgtgggt cctgggcttc atatggggag aaattaaaca gatgtgggat
1501 ggcggacttc aggactacat ccatgattgg tggaatctaa tggactttgt aatgaactcc
1561 ttatatttag caacaatctc cttgaaaatt gttgcatttg taaagtacag tgccttaat
1621 ccacgagaat catgggacat gtggcatccc actctggtgg cagaggcttt atttgcattt
1681 gcaaacatct tcagttctct gcgtctgatc tcaactgtta ctgcaaattc tcacctggga
1741 cctctgcaaa tatctctggg aagaatgctc ctggacattt tgaagtttct attcatatac
1801 tgccttgtgt tgctagcatt tgcaaatggc ctaaatacaat tgtacttcta ttatgaagaa
1861 acgaaagggg taacctgcaa aggcataaga tgtgaaaagc agaataatgc attttcaacg
1921 ttatttgaga cactgcagtc cctgttttgg tcaatatttg ggctcatcaa tttatattg
1981 accaatgtca aagcacagca tgaatttact gaggttgttg gtgccaccat gtttgggaca
2041 tacaatgtca tctctctggt tgttctactc aacatgttaa tagctatgat gaataattct
2101 taccaactga ttgctgacca tgcagatata gaatggaaat ttgcacgaac aaagctttgg
2161 atgagttatt ttgaagaagg aggtactctg cctactccct tcaatgtcat cccgagcccc
2221 aagtctctct ggtacctgat caaatggatc tggacacact tgtgcaagaa aaagatgaga
2281 agaaagccag aaagttttgg aacaataggg aggcgagctg ctgataactt gagaagacat
2341 caccaatacc aagaagtat gaggaacctg gtgaagcgat acgttgctgc aatgattaga
2401 gatgctaaaa ctgaagaagg cctgaccgaa gagaacttta aggaactaaa gcaagacatt
2461 tctagtttcc gctttgaagt cctgggatta ctaagaggaa gcaaactttc cacaatacaa
2521 tctgcgaatg cctcgaagga gtcttcaaat tcggcagact cagatgaaaa gagtgatagc
2581 gaaggtaata gcaaggacaa gaaaaagaat ttcagccttt ttgatttaac caccctgatt
2641 catccgagat cagcagcaat tgcctctgaa agacataaca taagcaatgg ctctgcctg
2701 gtggttcagg agccgcccag ggagaagcag agaaaagtga attttgtgac cgatatcaaa
2761 aactttgggt tatttcatag acgatcaaaa caaatgctg ctgagcaaaa tgcaaacaa
2821 atcttctctg tttcagaaga agttgctctg caacaggctg caggaccact tgagagaaat
2881 atccaactgg aatctcgagg attagcttca cggggtgacc tgagcattcc cggctcagt
2941 gaacaatgtg tgttagtaga ccatagagaa aggaatacgg acacactggg gttacaggta
3001 ggaaagagag tgtgtccatt caagtacagag aaggtggtgg tggaggacac ggttctata
3061 ataccaaagg agaaacatgc aaaagaagag gactctagta tagactatga tctaaacctc

```

Figure 2-1

3/5

```
3121 ccagacacag tcacccacga agattacgtg accacaagat tgtgatactt gaaggaggaa
3181 gcgtttacca tacacatacg tattttccgt agtgctctgg gtgggggaaa atgtttaaat
3241 tgtattagca aatgctaact tacactttat agcatttatc agctgtggca tattacctgt
3301 aacatgttta aattaaggca aaggcaatca aaaacctttt tgttttgtag cctgcttttg
3361 ctttcacaat ttgtcttaca attgtttttg ttaataaata aatgcacctt gaaaaaaaaa
3421 aaaaaaaaaa aaaaaaaaaa
```

Figure 2-2

# TRPC4 Antisense Treatment Reduces Neuropathic Pain




Figure 3B

Figure 3A

# TRPC4 Antisense Treatment Reduces Inflammatory Pain




Figure 4B

Figure 4A